{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:34:36Z","timestamp":1793208876297,"version":"4.5.0"},"reference-count":17,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,11]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>Outcomes for relapsed Ewing sarcoma remain poor. The RIST regimen (rapamycin, irinotecan, dasatinib, temozolomide) provides a targeted biological alternative to standard salvage chemotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>We report 3 patients treated with RIST for relapsed Ewing sarcoma.<\/jats:p>\n                    <jats:p>Results:<\/jats:p>\n                    <jats:p>One patient with measurable disease achieved an early partial response before progressing at 9 months. Two patients received RIST as post\u2013local-therapy consolidation with no evidence of disease, maintaining disease control for 41 and 44 months. Toxicities were manageable and primarily hematologic, without treatment discontinuations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>Prolonged outpatient RIST administration is feasible, and its role as multimodality consolidation warrants further prospective evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/mph.0000000000003284","type":"journal-article","created":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T19:00:32Z","timestamp":1790622032000},"page":"425-431","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Clinical Experience With RIST-Based Multimodality Therapy in Relapsed Ewing Sarcoma: A Descriptive Single-center Case Series"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8418-2491","authenticated-orcid":false,"given":"Mahdi","family":"Asleh","sequence":"first","affiliation":[{"name":"Department of Pediatric Hemato-oncology, Saban Pediatric Medical Center, Soroka University Medical Center"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yotam","family":"Eshel","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-oncology, Saban Pediatric Medical Center, Soroka University Medical Center"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam","family":"Ben Harosh","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-oncology, Saban Pediatric Medical Center, Soroka University Medical Center"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-0804-4767","authenticated-orcid":false,"given":"Aya","family":"Khalaila","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-oncology, Saban Pediatric Medical Center, Soroka University Medical Center"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abed","family":"Abu Quider","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-oncology, Saban Pediatric Medical Center, Soroka University Medical Center"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Levin","sequence":"additional","affiliation":[{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev"},{"name":"Nuclear Medicine Institute, Soroka Medical Center, Beer Sheva, Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hagit","family":"Miskin","sequence":"additional","affiliation":[{"name":"Department of Pediatric Hemato-oncology, Saban Pediatric Medical Center, Soroka University Medical Center"},{"name":"Faculty of Health Sciences, Ben-Gurion University of the Negev"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,9,28]]},"reference":[{"key":"R1-20261028","doi-asserted-by":"crossref","first-page":"4028","DOI":"10.1002\/cncr.35537","article-title":"Consensus recommendations for systemic therapies in the management of relapsed Ewing sarcoma: a report from the National Ewing Sarcoma Tumor Board","volume":"130","author":"Gupta","year":"2024","journal-title":"Cancer"},{"key":"R2-20261028","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.2147\/OTT.S170585","article-title":"Management of recurrent Ewing sarcoma: challenges and approaches","volume":"12","author":"Van Mater","year":"2019","journal-title":"OTT"},{"key":"R3-20261028","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1002\/pbc.20697","article-title":"Temozolomide and intravenous irinotecan for treatment of advanced Ewing sarcoma","volume":"48","author":"Wagner","year":"2007","journal-title":"Pediatric Blood Cancer"},{"key":"R4-20261028","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1002\/pbc.22206","article-title":"Irinotecan and temozolomide for Ewing sarcoma: the Memorial Sloan-Kettering experience","volume":"53","author":"Casey","year":"2009","journal-title":"Pediatric Blood Cancer"},{"key":"R5-20261028","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/pbc.24621","article-title":"Vincristine, irinotecan, and temozolomide in patients with relapsed and refractory Ewing sarcoma","volume":"60","author":"Raciborska","year":"2013","journal-title":"Pediatric Blood Cancer"},{"key":"R6-20261028","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1186\/s12885-022-09469-5","article-title":"Irinotecan plus temozolomide in relapsed Ewing sarcoma: an integrated analysis of retrospective studies","volume":"22","author":"Wang","year":"2022","journal-title":"BMC Cancer"},{"key":"R7-20261028","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1158\/1078-0432.CCR-22-3546","article-title":"Longer versus shorter schedules of vincristine, irinotecan, and temozolomide (VIT) for relapsed or refractory Ewing sarcoma: a randomized controlled phase 2 trial","volume":"29","author":"Xu","year":"2023","journal-title":"Clin Cancer Res"},{"key":"R8-20261028","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S1470-2045(24)00202-X","article-title":"Irinotecan and temozolomide in combination with dasatinib and rapamycin versus irinotecan and temozolomide for patients with relapsed or refractory neuroblastoma (RIST-rNB-2011): a multicentre, open-label, randomised, controlled, phase 2 trial","volume":"25","author":"Corbacioglu","year":"2024","journal-title":"Lancet Oncol"},{"key":"R9-20261028","doi-asserted-by":"crossref","first-page":"9282","DOI":"10.1038\/sj.onc.1207081","article-title":"Rapamycin induces the fusion-type independent downregulation of the EWS\/FLI-1 proteins and inhibits Ewing\u2019s sarcoma cell proliferation","volume":"22","author":"Mateo-Lozano","year":"2003","journal-title":"Oncogene"},{"key":"R10-20261028","doi-asserted-by":"crossref","first-page":"djw182","DOI":"10.1093\/jnci\/djw182","article-title":"IGF-1R and mTOR blockade: novel resistance mechanisms and synergistic drug combinations for Ewing sarcoma","volume":"108","author":"Lamhamedi-Cherradi","year":"2016","journal-title":"JNCI J Natl Cancer Inst"},{"key":"R11-20261028","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3892\/ol.2015.3184","article-title":"The importance of Src signaling in sarcoma","volume":"10","author":"Chen","year":"2015","journal-title":"Oncol Lett"},{"key":"R12-20261028","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/pbc.24874","article-title":"Phase 1 trial of temsirolimus in combination with irinotecan and temozolomide in children, adolescents and young adults with relapsed or refractory solid tumors: a children\u2019s oncology group study","volume":"61","author":"Bagatell","year":"2014","journal-title":"Pediatric Blood Cancer"},{"key":"R13-20261028","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/1752-1947-7-223","article-title":"The CARE guidelines: consensus-based clinical case reporting guideline development","volume":"7","author":"Gagnier","year":"2013","journal-title":"J Med Case Reports"},{"key":"R14-20261028","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.jclinepi.2017.04.026","article-title":"CARE guidelines for case reports: explanation and elaboration document","volume":"89","author":"Riley","year":"2017","journal-title":"J Clin Epidemiol"},{"key":"R15-20261028","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R16-20261028","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","article-title":"Appropriate use and reporting of uncontrolled case series in the medical literature","volume":"151","author":"Kempen","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R17-20261028","doi-asserted-by":"crossref","first-page":"3680","DOI":"10.1200\/JCO.2016.68.1858","article-title":"Assessment of imaging modalities and response metrics in Ewing sarcoma: correlation with survival","volume":"34","author":"Koshkin","year":"2016","journal-title":"JCO"}],"container-title":["Journal of Pediatric Hematology\/Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003284","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T17:00:22Z","timestamp":1793206822000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MPH.0000000000003284"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,28]]},"references-count":17,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/mph.0000000000003284","relation":{},"ISSN":["1077-4114","1536-3678"],"issn-type":[{"value":"1077-4114","type":"print"},{"value":"1536-3678","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,28]]},"assertion":[{"value":"2026-05-19","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-09-01","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}